OncologyTube Professional - Patients Click Here
380,643 video views
Loading........
Description: If resistance occurs to second generation TKIs in chronic myeloid leukemia (CML) patients, what is the next best option? Here, Giuseppe Saglio, MD, of the University of Turin, Turin, Italy, explores t...
02:14
If resistance occurs to second generation TKIs in chronic myeloid leukemia (CML) patients, what is the next best option? Here, Giuseppe Saglio, MD, of the University of Turin, Turin, Italy, explores this important question. He highlights what data from the ENESTnd (NCT00471497) and ENEST1st (NCT0106...
by:VJHemOnc | 2 views
03:15
Venetoclax monotherapy has yielded disappointing results in acute myeloid leukemia (AML) because resistance develops along with the propagation of MCL1-expressing clones. Here, Marina Konopleva, MD, PhD, of the MD Anderson Cancer Center, Houston, TX, discusses different ways to inhibit MCL1 expressi...
by:VJHemOnc | 9 views
01:35
Alexander Perl, MD, of the University of Pennsylvania, Philadelphia, PA, discusses the effectiveness of drugs currently on the market to treat acute myeloid leukemia (AML) at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting, held in Houston, TX. Dr Perl explains how the FLT3 inhibitors...
by:VJHemOnc | 3 views
02:41
FCR chemoimmunother​apy is most effective in the IGVH mutated, non-17p deletion chronic lymphocytic leukemia (CLL) patient subgroup. With the advent of novel drugs in the field however, Nitin Jain, MD, from the MD Anderson Cancer Center, Houston, TX, believes that this therapy could be improved upon. In this interview, recorded at the 2018 Society o...
by:VJHemOnc | 2 views
03:38
While CAR T-cells are an approved therapy option in acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL), the research in chronic lymphocytic leukemia (CLL) is somewhat behind. In this video, recorded at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, William Wierda, MD, PhD, of the MD Anderson...
by:VJHemOnc | 3 views
01:52
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Valeria Santini, MD, of the University of Florence, Florence, Italy, discusses a new concept in the pathophysiology of myelodysplastic syndromes (MDS): that inflammation can be an effective indicator for MDS and its progression. She explains how cytokine S1...
by:VJHemOnc | 2 views
02:35
The ENESTop trial (NCT01698905) investigated treatment-free remission (TFR) in patients with chronic myeloid leukemia (CML) after discontinuing nilotinib, following the acheivement of a deep molecular response. Here, Timothy Hughes, MD, FRACP, FRCPA, of the Royal Adelaide Hospital, Adelaide, Austral...
by:VJHemOnc | 1 views
01:26
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Rob Pieters, MD, PhD, of Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands, discusses current research and drug developments to treat mixed lineage leukemia (MLL) rearranged acute lymphoblastic leukemia (ALL). Prof. Pieters states that...
by:VJHemOnc | 1 views
04:30
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Simon Rule, MD, from Plymouth University, Plymouth, UK, outlines the current standards of care for both young and elderly patients with mantle cell lymphoma (MCL). He highlights some current trials which are...
by:VJHemOnc | 1 views
02:33
EZH2 mutations are associated with a poor prognosis in myelodysplastic syndromes (MDS). In this video, recorded at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Rashmi Kanagal-Shamann​a, MD, of the MD Anderson Cancer Center, Houston, TX, discusses her work investigating the role of EZH2 mutations in MDS pathology. Sh...
by:VJHemOnc | 3 views

About VJHemOnc
Description: The Video Journal of Hematological Oncology (VJHemOnc) is an independent, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve understanding and awareness of hematological malignancies.

Links
Channel Url:

Website:


Social Links: